Idiopathic pulmonary fibrosis: Present understanding and future options

European Respiratory Review

Volumn 20, Issue 121, 2011, Pages 132-133

  du Bois, R M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DISRUPTION; CLINICAL STUDY; DISEASE COURSE; EDITORIAL; FIBROSING ALVEOLITIS; HISTOPATHOLOGY; HUMAN; LUNG ALVEOLUS EPITHELIUM; MORTALITY; OPTIMISM; UNITED STATES;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; TREATMENT OUTCOME;

EID: 80052533421     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00001511     Document Type: Editorial

References (20)

1. Olson AL, Swigris JJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007; 176: 277-284.
2. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, National Cancer Institute 2011. http://seer.cancer.gov/csr/1975_2007
3. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-296.
4. Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med 1998; 158: 220-225.
5. Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon c-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341: 1264-1269.
6. Johnson MA, Kwan S, Snell NJ, et al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280-288.
7. Noble PW, Albera C, Bradford W, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY: two randomised trials). Lancet 2011; 377: 1760-1769.
8. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebocontrolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-1047.
9. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon c-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-133.
10. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
11. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-1482.
12. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebocontrolled trial. Am J Respir Crit Care Med 2008; 178: 948-955.
13. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon c-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-228.
14. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010; 181: 604-610.
15. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
16. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
17. Valeyre D. Towards a better diagnosis of idiopathic pulmonary fibrosis. Eur Respir Rev 2011; 20: 108-113.
18. Albera C. Challenges in idiopathic pulmonary fibrosis: the points on end-points. Eur Respir Rev 2011; 20: 195-200.
19. Costabel U. Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients? Eur Respir Rev 2011; 20: 201-207.
20. Egan J. Follow-up and non-pharmacological management of the idiopathicpulmonaryfibrosispatient. EurRespirRev 2011; 20: 114-117.